Predictive modeling of COPD exacerbation rates using baseline risk factors

Dave Singh, John R. Hurst, Fernando J. Martinez, Klaus F. Rabe, Mona Bafadhel, Martin Jenkins, Domingo Salazar, Paul Dorinsky and Patrick Darken

Abstract

Background: Demographic and disease characteristics have been associated with the risk of chronic obstructive pulmonary disease (COPD) exacerbations. Using previously collected multinational clinical trial data, we developed models that use baseline risk factors to predict an individual’s rate of moderate/severe exacerbations in the next year on various pharmacological treatments for COPD.

Methods: Exacerbation data from 20,054 patients in the ETHOS, KRONOS, TELOS, SOPHOS, and PINNACLE-1, PINNACLE-2, and PINNACLE-4 studies were pooled. Machine learning was used to identify predictors of moderate/severe exacerbation rates. Important factors were selected for generalized linear modeling, further informed by backward variable selection. An independent test set was held back for validation.

Results: Prior exacerbations, eosinophil count, forced expiratory volume in 1 s percent predicted, prior maintenance treatments, reliever medication use, sex, COPD Assessment Test score, smoking status, and region were significant predictors of exacerbation risk, with response to inhaled corticosteroids (ICSs) increasing with higher eosinophil counts, more prior exacerbations, or additional prior treatments. Model fit was similar in the training and test set. Prediction metrics were ~10% better in the full model than in a simplified model based only on eosinophil count, prior exacerbations, and ICS use.

Conclusion: These models predicting rates of moderate/severe exacerbations can be applied to a broad range of patients with COPD in terms of airway obstruction, eosinophil counts, exacerbation history, symptoms, and treatment history. Understanding the relative and absolute risks related to these factors may be useful for clinicians in evaluating the benefit: risk ratio of various treatment decisions for individual patients.

Clinical trials registered with www.clinicaltrials.gov (NCT02465567, NCT02497001, NCT02766608, NCT02727660, NCT01854645, NCT01854658, NCT02343458, NCT03262012, NCT02536508, and NCT01970878)

Keywords: chronic obstructive pulmonary disease, exacerbations, ICS/LAMA/LABA, machine learning, prediction model, triple therapy

Received: 19 November 2021; revised manuscript accepted: 30 May 2022.

Introduction

Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with adverse health outcomes, including greater risk for future exacerbations, lung function decline, worsening quality of life, and increased risk of mortality.¹⁻³ In addition, exacerbations account for the majority of healthcare costs associated with COPD, to which those leading to hospitalization contribute significantly.⁴ Accordingly, the prevention of exacerbations is a key goal of COPD management.⁵

Several disease characteristics are known to increase the risk of COPD exacerbations, including previous exacerbation history, greater airflow obstruction or symptom severity, and comorbidities, including...
diabetes, cancer, heart failure, and gastroesophageal reflux. Also, blood eosinophil count is a predictor of exacerbation risk and a modifier of treatment response to inhaled corticosteroids (ICSs), with greater reductions in exacerbation rates as eosinophil counts increase. Therefore, it is important to tailor interventions according to the individual patient factors that contribute to exacerbation risk.

Current treatment algorithms from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommend using exacerbation history and symptom burden to determine the most appropriate inhaled treatment. Blood eosinophil counts are also considered useful for determining when to use an ICS-containing treatment regimen. More recently, several predictive models have been developed that incorporate additional clinical and biological characteristics, which may predict future exacerbation risk. Covariates included in these models cover a range of demographic characteristics, previous medication history, and disease severity characteristics such as forced expiratory volume in 1 s percent (FEV1%) predicted and exacerbation history; however, the risk of experiencing a COPD exacerbation is also influenced by the effects of pharmacological treatment, which may vary as a function of patient characteristics. Therefore, we used previously collected multinational clinical trial data from more than 20,000 patients to develop a model that would predict the effects of pharmacological treatment on exacerbation risk and apply to individuals within broad populations of patients with COPD.

### Methods

#### Source data

The model was developed using data from the Phase III clinical development programs of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI), budesonide/formoterol fumarate (BFF) MDI, and glycopyrrolate/formoterol fumarate (GFF) MDI. Patients were randomized to treatment with various combinations of the ICS budesonide (320 or 160 µg), the long-acting muscarinic antagonist (LAMA) glycopyrrolate (18 µg), and the long-acting β2-agonist (LABA) formoterol fumarate (FF; 9.6 µg), or placebo, with the specific treatment arms varying by study (Table 1).

| Study                  | N     | Study duration | Key inclusion criteria                                                                 | Treatments included          |
|------------------------|-------|----------------|----------------------------------------------------------------------------------------|------------------------------|
| ETHOS13                | 8509  | 52 wks         | • FEV1 25−<65% • ≥2 inhaled maintenance therapies • CAT ≥10 • ≥1 exacerbation in prior year | BGF 320/18/9.6 µg BGF 160/18/9.6 µg BFF 320/9.6 µg GFF 18/9.6 µg |
| KRONOS + Extension Studies12 | 1896  | 24 wks + 28-wk extensions | • FEV1 25−<80% • ≥2 inhaled maintenance therapies • CAT ≥10 • No exacerbation requirement | BGF 320/18/9.6 µg BFF 320/9.6 µg [MDI] BFF 320/9 µg [DPI] GFF 18/9.6 µg |
| TELOS20                | 2361  | 24 wks         | • FEV1 <80% • ≥1 inhaled maintenance therapy • CAT ≥10 • No exacerbation requirement | BFF 320/9.6 µg [MDI] BFF 320/9 µg [DPI] BFF 160/9.6 µg BD 320 µg FF 9.6 µg |
| SOPHOS21               | 1843  | 12–52 wks [variable] | • FEV1 25−<80% • ≥1 inhaled maintenance therapy • CAT ≥10 • ≥1 exacerbation in prior year | BFF 320/9.6 µg BFF 160/9.6 µg FF 9.6 µg |
| PINNACLE-1 + PINNACLE-3 Extension Study22 | 2096  | 24 wks + 28-wk extension | • FEV1 <80% • No requirements for inhaled maintenance therapy, symptoms, or exacerbations | GFF 18/9.6 µg GP 18 µg FF 9.6 µg Placebo |

(Continued)
The database included pooled exacerbation data from a total of 20,054 patients from ETHOS (NCT02465567), KRONOS (NCT02497001), TELOS (NCT02727660), PINNACLE-1 (NCT01854645), PINNACLE-2 (NCT01854658), and PINNACLE-4 (NCT02343458) (Table 1). Data from extension studies (up to 1 year in duration) of KRONOS (NCT03262012, NCT02536508) and PINNACLE-1 and PINNACLE-2 (PINNACLE-3; NCT01970878) were also included. All treatments were delivered via a single Aerosphere inhaler (AstraZeneca), except for the BFF dry powder inhaler (Symbicort Turbuhaler; AstraZeneca) used in KRONOS and TELOS.

All studies enrolled patients 40–80 years of age with moderate-to-very severe COPD (FEV₁/FVC ratio < 0.7 and FEV₁ < 80% predicted (<65% in ETHOS) and a smoking history of ≥10 pack-years. In addition, SOPHOS and ETHOS required a history of ≥1 exacerbation in the previous year. The PINNACLE studies did not have any entry criteria regarding prior treatment or symptoms; all other studies required that patients were symptomatic [COPD Assessment Test (CAT) score ≥10] despite receiving ≥1 (TELOS, SOPHOS) or ≥2 (KRONOS, ETHOS) COPD maintenance medications at study entry.

### Model development

The endpoint of interest was the annualized rate of moderate/severe exacerbations (defining moderate exacerbations as those that require treatment with systemic corticosteroids or antibiotics, or both, and severe exacerbations as those that require hospitalization or those that resulted in death). Exacerbation data only included events that occurred during randomized treatment. Modeling was conducted using the statistical software R, and both machine learning techniques and traditional statistical modeling approaches were utilized.

A preliminary model was developed using negative binomial generalized linear modeling (GLM) with data from all studies except ETHOS. A statistical analysis plan was finalized, including steps that would be completed following the unblinding of ETHOS data. Predictors were investigated based on prior literature reporting clinical, physiological, and demographic risk factors for exacerbations. The set of proposed predictors included blood eosinophil count (log-transformed), ICS use, sex, FEV₁ (post-bronchodilator percent predicted), exacerbation history (number in last year), smoking status (current/former), CAT score, prior maintenance therapies, and average daily reliever medication use (in puffs/day). Interaction terms with budesonide were proposed for ICS use, eosinophil count, smoking status, and eosinophil count by smoking status.

Following the completion of the ETHOS study, a wide range of prospectively named potential predictors available in all studies were considered for the final model development. These additional potential predictors included age, body mass index, height, race, duration of COPD, GOLD classifications A–D, prior ICS use, prior LAMA use, prior LABA use, number of pack-years.
smoked, number of severe exacerbations in the last year, blood neutrophil count, medical history of gastroesophageal reflux disease, cardiometabolic medical history (including diabetes, hypertension, and high cholesterol), region, study, percent reversibility to salbutamol, and other lung function parameters such as FVC, forced expiratory flow at 25–75% of FVC (FEF25–75), and peak expiratory flow (PEF). No patients had missing exacerbation outcomes, and no covariate had greater than 1.25% missing data. As such, only complete cases were used in model development.

The pooled dataset was randomly split into a training set and a test set (stratified by study and treatment), containing 85% and 15% of the population, respectively, to develop the final model (following unblinding of the ETHOS data). Among each pair of covariates with a correlation ≥0.75, one predictor was chosen based on clinical relevance and precedent, leaving a set of predictors taken forward to machine learning.

Machine learning methods – including gradient boosting\(^25\) (with virtual twins),\(^26,27\) GLMtree,\(^28–30\) GUIDE,\(^31,32\) and Elastic Nets\(^33\) – were used on the training set to assess variable importance, confirm proposed predictors, and identify additional predictors, including interactions with treatment terms, which would add predictive value. Additional predictors of interest were then incorporated into the final negative binomial GLM. Time at risk was used as an offset variable. This selection was further informed by backward variable selection to ensure the model was parsimonious, retaining covariates or interactions with \(p < 0.1\), or up to \(p = 0.2\) if there was considerable prior literature supporting their inclusion. Treatment covariates were included to ensure unconstrained prediction was possible for each combination therapy.

In addition to the full model, a simplified model was also tested, including only three predictors known to be available in most patient care settings (exacerbation history, eosinophil count, and prior ICS treatment). Results for the full and simplified models were compared to determine the value of the additional predictors.

Model fit was also assessed on the test set using the median absolute difference between observed and predicted exacerbation rates, and for the prediction of patients with 0 versus ≥1 exacerbation in the following year, in terms of area under the receiver operating characteristic (ROC) curve, positive predictive value, and negative predictive value.

From the final models, rate ratios (RR) and 95% confidence intervals (CIs) were used to present each predictor’s role. Predicted exacerbation rates for a selection of example patients were derived, setting other covariates to typical values close to the median or mode for the dataset.

**Results**

**Population characteristics**

Overall, 19,194 patients had complete data available and were included in the model development. The population included patients from North America, South America, Europe, Asia, South Africa, and Australasia.

The demographic and disease characteristics of the training set (\(n = 16,314\)) and test set (\(n = 2880\)) are shown in Table 2. Demographics were comparable between the two datasets. A majority of patients in both datasets (92%) had moderate or severe COPD, and 65% had experienced ≥1 moderate or severe exacerbation in the past year. The mean CAT score was approximately 19 in both datasets (range: 0–40).

**Model development**

Signal searching was carried out to determine optimal predictors. Results of important prognostic predictors from gradient boosting are shown in Figure S1 in the Online Supplement (other machine learning results not shown). The expected model covariates (based on prior literature) of exacerbation history, eosinophil count, and prior ICS treatment). Results for the full and simplified models were compared to determine the value of the additional predictors.

Region was added to the final full model, and prior maintenance therapies were incorporated using separate factors for prior ICS use, prior LAMA use, and prior LABA use to provide a complete characterization of prior treatment.
Table 2. Population characteristics of the training and test sets.

|                           | Training set  | Test set      |
|---------------------------|---------------|---------------|
|                           | \(n = 16,314\) | \(n = 2880\)  |
| Age, years                |               |               |
| Mean (SD)                 | 64.3 (7.8)    | 64.6 (7.9)    |
| Range                     | 40–81         | 40–80         |
| Male sex                  | 10,022 (61.4%)| 1734 (60.2%)  |
| Race                      |               |               |
| White                     | 13,270 (81.3%)| 2332 (81.0%)  |
| Asian                     | 1865 (11.4%)  | 335 (11.6%)   |
| Black                     | 692 (4.2%)    | 131 (4.5%)    |
| Other                     | 487 (3.0%)    | 82 (2.8%)     |
| Region                    |               |               |
| United States and Canada  | 8066 (49.4%)  | 1429 (49.6%)  |
| Western Europe            | 2318 (14.2%)  | 428 (14.9%)   |
| Eastern Europe            | 2038 (12.5%)  | 371 (12.9%)   |
| Latin America             | 1551 (9.5%)   | 235 (8.2%)    |
| China                     | 1205 (7.4%)   | 202 (7.0%)    |
| Asia (non-China)          | 584 (3.6%)    | 119 (4.1%)    |
| Australasia and South Africa | 552 (3.4%) | 96 (3.3%)     |
| Smoking status            |               |               |
| Current smoker            | 7245 (44.4%)  | 1319 (45.8%)  |
| Former smoker             | 9069 (55.6%)  | 1561 (54.2%)  |
| Mean COPD duration, years | 7.8 (6.2)     | 7.7 (6.1)     |
| Disease severity          |               |               |
| Mild                      | 28 (0.2%)     | 3 (0.1%)      |
| Moderate                  | 7066 (43.3%)  | 1250 (43.4%)  |
| Severe                    | 7986 (49.0%)  | 1397 (48.5%)  |
| Very severe               | 1232 (7.6%)   | 230 (8.0%)    |
| FEV1% predicted           |               |               |
| Mean (SD)                 | 48.3 (13.1)   | 48.1 (13.2)   |
| Range                     | 19–95         | 16–88         |
| Mean reliever medication  | 3.1 (3.3)     | 3.2 (3.3)     |
| Exacerbation history in the past year |           |               |
| ⩾1 moderate/severe        | 10,646 (65.3%)| 1868 (64.9%)  |
| ⩾1 severe                 | 2258 (13.8%)  | 393 (13.6%)   |

(Continued)
### Table 2. (Continued)

| Blood eosinophil count | Training set \((n = 16,314)\) | Test set \((n = 2880)\) |
|------------------------|-------------------------------|------------------------|
| Geometric mean, cells/mm\(^3\) | 162                           | 160                    |
| <100 cells/mm\(^3\) | 2824 (17.3%)                  | 52 (18.8%)             |
| 100–<300 cells/mm\(^3\) | 10,776 (66.1%)                | 1847 (64.1%)           |
| ≥300 cells/mm\(^3\) | 2714 (16.6%)                  | 491 (17.0%)            |
| CAT score            |                               |                        |
| Mean (SD)            | 19.1 (6.8)                    | 19.2 (6.7)             |
| Range                | 0–40                          | 0–40                   |
| Treatment received   |                               |                        |
| BGF 320/18/9.6 µg    | 2278 (14.0%)                  | 402 (13.9%)            |
| BGF 160/18/9.6 µg    | 1782 (10.9%)                  | 314 (10.9%)            |
| BFF 320/9.6 µg\(^a\) | 3545 (21.7%)                  | 625 (21.7%)            |
| BFF 160/9.6 µg       | 1050 (6.4%)                   | 186 (6.5%)             |
| GFF 18/9.6 µg        | 3585 (22.0%)                  | 633 (22.0%)            |
| BD 320 µg            | 168 (1.0%)                    | 30 (1.0%)              |
| GP 18 µg             | 1148 (7.0%)                   | 202 (7.0%)             |
| FF 9.6 µg            | 2190 (13.4%)                  | 387 (13.4%)            |
| Placebo              | 568 (3.5%)                    | 101 (3.5%)             |
| Prior maintenance treatment |                       |                        |
| ICS/LAMA/LABA        | 4795 (29.3%)                  | 807 (28.0%)            |
| ICS/LABA             | 5318 (32.6%)                  | 958 (33.3%)            |
| LAMA/LABA            | 2287 (14.0%)                  | 428 (14.9%)            |
| ICS/LAMA             | 245 (1.5%)                    | 36 (1.3%)              |
| ICS only             | 364 (2.2%)                    | 54 (1.9%)              |
| LAMA only            | 935 (5.7%)                    | 152 (5.3%)             |
| LABA only            | 332 (2.0%)                    | 69 (2.4%)              |
| None                 | 2038 (12.5%)                  | 376 (13.1%)            |

BD, budesonide; BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FEV\(_1\), forced expiratory volume in 1 s; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ICS, inhaled corticosteroid; LABA, long-acting β\(_2\)-agonist; LAMA, long-acting muscarinic antagonist; MDI, metered dose inhaler; SD, standard deviation.

Data are \(n\) (%) unless otherwise specified.

\(^a\)Includes BFF MDI (320/9.6 µg) and DPI (320/9 µg).
history. Smoking status was not found to be of high importance but was retained due to knowledge from the literature and its potential to be important in interaction terms. Several additional spirometry parameters (e.g., FEF_{25-75}, reversibility, and PEF) were found to be important, but given their correlation with FEV1% predicted or limited availability in clinical practice, they were not added to the model. The predictor variable relating to study (ETHOS, KRONOS, etc.) was removed from the model to increase generalizability.

Based on results from machine learning, several variables were determined to potentially show a differential response depending on the use of budesonide-containing therapy in the following year. As a result, expected interaction terms with eosinophil count, prior ICS use, and smoking status were retained. Additional interactions with exacerbation history, prior LABA use, and reliever medication usage were included, as well as an interaction between eosinophil count and smoking status. A three-way interaction between budesonide use, eosinophil count, and smoking status was not found to be of value, as the relationship between eosinophil count and the benefit of budesonide did not vary significantly depending upon smoking status. The backward selection step also removed interactions between budesonide use and FEV1% predicted, and between glycopyrrolate use and exacerbation history.

In the final full model, a higher number of exacerbations in the prior year, higher eosinophil count, each additional prior maintenance treatment (ICS, LAMA, or LABA), a higher number of puffs/day of reliever medication, lower FEV1% predicted, female sex, higher CAT score, region, and current smoking were found to be significant predictors of exacerbation risk, with prior exacerbations, eosinophil count, and prior therapy as modifiers of ICS response (Table 3). Full model coefficients for the final model are provided in Table S1 in the Online Supplement.

Model fit, as assessed using rootograms, demonstrated that the distribution of the predicted number of exacerbations in the following year was similar to the actual distribution with a median absolute difference between actual and predicted exacerbation rates of 0.77 for the full model. The area under the ROC curves, at 0.70, demonstrated reasonable prediction of patients with and without an exacerbation in the following year, and performance metrics were similar in both the training set and test set (see Figure S2 in the Online Supplement). For a negative predictive value of 80%, the training and test sets showed positive predictive values of 47% and 48%, respectively, for the full model (Table 3).

Prediction metrics were ~10% better, in relative terms, in the full model than in the simplified model, based only on exacerbation history, eosinophil count, and ICS use (Table 3; Table S2 in the Online Supplement). The relationship between eosinophil count and exacerbation rates was similar in the full and simplified models.

**Prediction of exacerbation rates**

The impact of selected prognostic factors on exacerbation rates, regardless of treatment in the following year, is illustrated in Figure 1.

The following main effects were associated with increased risk of an exacerbation, but were not found to modify the relative benefit of any of the treatments: female sex (RR: 1.31, 95% CI: 1.23–1.38); prior LAMA use (RR: 1.23, 95% CI: 1.16–1.31); FEV1% predicted (RR: 1.36, 95% CI: 1.30–1.43 for a 20% reduction in FEV1% predicted); and CAT score (RR: 1.14, 95% CI: 1.09–1.19 for a 10-point increase in CAT score) (Figure 1(a)).

Current smoking, a higher number of puffs/day of reliever medication, prior LABA use, prior ICS use, and additional COPD exacerbations in the previous year were associated with increased risk of a moderate/severe exacerbation, with a differential response depending on budesonide use (Figure 1(b)).

The model was then applied to several example patient types to illustrate the predicted exacerbation rate with various treatments, according to blood eosinophil count, prior therapy, and exacerbation history. Results are shown in Figure 2 for a patient with the following characteristics, representing the approximate median values for the dataset: former smoker, from North America, FEV1 45% of predicted, CAT score of 20, and using three puffs/day of reliever medication. Consistent with KRONOS and ETHOS results,12,13 these predictions show a greater benefit of ICS-containing treatments over LAMA/LABA treatment in patients with higher eosinophil counts.
(regardless of prior treatment and exacerbation history), with the magnitude of expected benefit increasing as eosinophil counts increased. Larger benefits were also demonstrated in patients with more prior maintenance therapies and a greater number of previous exacerbations.

Table 3. Predictive performance of full and simplified prediction models of the rate of moderate or severe COPD exacerbations.

| Model covariates                                                                 | Full model                                                                 | Simplified model                                                                 |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Model covariates                                                               | Moderate/severe COPD exacerbation rate ~ offset[Log (Exposure)] + Intercept | Moderate/severe COPD exacerbation rate ~ offset[Log (Exposure)] + Intercept      |
| Prognostic covariates                                                          | + No. of exacerbations in prior year***                                    | + No. of exacerbations in prior year***                                          |
|                                                                                  | + log(Eosinophils)***                                                      | + log(Eosinophils)***                                                            |
|                                                                                  | + Prior ICS use***                                                         | + Prior ICS use***                                                               |
|                                                                                  | + Prior LABA use***                                                        |                                                                                  |
|                                                                                  | + Prior LAMA use***                                                        |                                                                                  |
|                                                                                  | + Mean daily reliever medication usage***                                  |                                                                                  |
|                                                                                  | + FEV1% predicted***                                                       |                                                                                  |
|                                                                                  | + Sex***                                                                   |                                                                                  |
|                                                                                  | + CAT score***                                                             |                                                                                  |
|                                                                                  | + Region***                                                                |                                                                                  |
|                                                                                  | + Smoking status**                                                         |                                                                                  |
|                                                                                  | + log(Eosinophils):Smoking status**                                         |                                                                                  |
| Treatment covariates                                                            | BD*** + GP*** + FF + BD:FF + GP:FF + BD:GP:FF                              | BD*** + GP* + FF** + BD:FF + GP:FF† + BD:GP:FF                                  |
| Interactions with ICS treatment                                                 | + BD × No. of exacerbations in prior year*                                 | + BD × No. of exacerbations in prior year***                                    |
|                                                                                  | + BD × log(Eosinophils)***                                                 | + BD × log(Eosinophils)***                                                      |
|                                                                                  | + BD × Prior ICS use*                                                      | + BD × Prior ICS use***                                                         |
|                                                                                  | + BD × Prior LABA use*                                                     |                                                                                  |
|                                                                                  | + BD × Mean daily reliever medication usage†                               |                                                                                  |
|                                                                                  | + BD × Smoking status                                                      |                                                                                  |
| Performance metrics                                                             | Training set                  | Test set                          | Training set                  | Test set                          |
| Median difference between predicted and actual rate                             | 0.77                         | 0.77                              | 0.86                         | 0.87                              |
| Area under ROC curve for prediction of 0 versus ≥1 exacerbations                | 0.70                         | 0.71                              | 0.67                         | 0.65                              |
| Positive predictive value                                                       | 47%                          | 48%                               | 44%                          | 45%                               |
| Negative predictive value                                                       | 80%                          | 80%                               | 80%                          | 80%                               |

ANOVA, analysis of variance; BD, budesonide; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; GP, glycopyrrolate; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; ROC, receiver operating characteristic.

Negative binomial generalized linear models.

Significance of sequential inclusion in model from ANOVA: ***p < 0.001; **p < 0.01; *p < 0.05; †p < 0.10; ‡p < 0.20.
Figure 1. Predictive factors of annual moderate/severe exacerbation rates: (a) main effects and (b) interaction terms with budesonide.

CAT, COPD Assessment Test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; F, female; FEV₁, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; M, male; N, no; Y, yes.

D Singh, JR Hurst et al.
Figure 2. Predicted annual moderate/severe exacerbation rate by blood eosinophil count (cells/mm$^3$) according to prior therapy and exacerbation history.

BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; exacs, moderate/severe exacerbations; FEV$_1$, forced expiratory volume in 1 s; GFF, glycopyrrolate/formoterol fumarate; ICS, inhaled corticosteroid; LABA, long-acting $\beta_2$-agonist; LAMA, long-acting muscarinic antagonist.

Banded areas denote the standard error. For all panels, results are for a patient with COPD with the following characteristics: 65-year-old, former smoker, from North America, FEV$_1$ 45% of predicted, CAT score of 20, using three puffs/day of reliever. For the training set, each panel represents the following proportion of patients in the source population: LAMA only, 0 exacs = 3.8%; LAMA only, 1 exacs = 1.3%; LAMA only, 2 exacs = 0.5%; ICS/LABA, 0 exacs = 9.7%; ICS/LABA, 1 exacs = 11.7%; ICS/LABA, 2 exacs = 9.4%; ICS/LAMA/LABA, 0 exacs = 4.5%; ICS/LAMA/LABA, 1 exacs = 12.0%; ICS/LAMA/LABA, 2 exacs = 9.9%.
Discussion
We developed models predicting moderate/severe exacerbation rates that could be applied to patients with COPD with a broad range of clinical and physiological features, including airway obstruction, blood eosinophil counts, exacerbation history, symptoms, and treatment history. These models allow for the comparison of various COPD treatments and an examination of their relative efficacy in different subgroups of patients, highlighting those who may derive the greatest benefit from triple therapy or ICS-containing therapies. Highly significant predictors included exacerbation history, FEV₁% predicted, eosinophil count, sex, region, CAT score, prior treatment, and reliever medication use. These risk factors may be used to judge the potential benefits of switching between treatments for a broad range of patients with COPD, not only those who require step-up due to continued symptoms or exacerbations.

Given that patients experience an integer number of exacerbations in a year, but predicted rates are continuous, the full model showed good agreement between predicted and observed exacerbation rates, with a positive predictive value of 48%, for a negative predictive value of 80%. Metrics were provided for a high negative predictive value such that patients were not falsely predicted to have no exacerbations. False-positive predictions of exacerbations in the following year would also occur, as illustrated by the positive predictive value. However, in clinical terms, false positives were considered less of a concern than false negatives and are inevitable when predicting a transient outcome (even patients with established exacerbation risk may not experience one every year).

Even a single exacerbation can result in negative health outcomes for patients. Therefore, proactively identifying patients predicted to have a high rate of exacerbations and optimizing treatment to prevent future exacerbations should be a key aim of COPD management. Notably, many of the risk factors shown to be important in our model can be modified or improved (e.g. FEV₁% predicted, smoking status, and CAT score), suggesting that exacerbation risk can be modulated through treatment and lifestyle changes. In addition, while current GOLD recommendations do incorporate symptom burden, exacerbation history, and eosinophil count as key factors in treatment decisions, our model quantifies the potential absolute differences in predicted exacerbation rates based on these parameters in patients receiving various treatments. These absolute differences may be more informative than relative risk reductions for healthcare providers to evaluate the benefit:risk ratio of various treatment decisions for individual patients. For example, a smaller relative treatment benefit may substantially impact patients with a high expected rate of exacerbations. In contrast, a larger relative benefit may have a more limited impact in those with a low expected exacerbation rate. The prediction of absolute exacerbation rates may also be useful when planning clinical trials to assess the likelihood of COPD exacerbations in different patient groups. For trials that require the occurrence of exacerbations to provide useful data, predicted rates could be used to enrich trial populations for patients most at risk of exacerbations.

As expected, our model showed that the greatest treatment benefits of ICS-containing treatments versus a LAMA/LABA would be predicted in patients with prior ICS use, prior exacerbation history, and a high eosinophil count. However, benefits of ICSs were observed even in patients without a history of exacerbations in the past year (particularly among those with high eosinophil counts). The reason for this observation may be that, in patients with prior ICS use, a lack of exacerbations in the previous year suggests that these patients had a positive response to their ICS treatment. While taking into account the limitations of documenting only 1 year of exacerbation history, these findings suggest that the use of ICSs, even in patients without recent exacerbations, may help prevent their occurrence in the future. Given that a single COPD exacerbation is associated with lung function decline and other adverse health outcomes, predicting the first event, and not just future events, is important for those without a history of previous exacerbation.

In general, our models agree with previous reports of risk factors for COPD exacerbations that were based on randomized controlled trials or observational studies. In line with the findings from these studies, prior exacerbation history and the severity of airflow obstruction and symptoms were among the most significant predictors of exacerbation rates in our models. However, in contrast to the findings of Bafadhel et al., the impact of smoking status was less substantial in our study. We did not find that the relationship between exacerbations, eosinophil count, and
budesonide used varied significantly according to smoking status, although there were interactions for budesonide use by smoking status and budeso-

nide use by eosinophil count. The reasons for this are unclear but may relate to the populations studied. In addition, while observational studies have found that comorbidities were strong predictors of future exacerbations, the clinical trials used to develop our models had exclusion criteria for clinically significant, uncontrolled diseases other than COPD, limiting the presence of some common comorbidities in our source data.

While several other predictive models for COPD exacerbations have been published, our models have several strengths compared with previous work. Many of the previously published predictive models for COPD exacerbations used source data from a single country or region. In contrast, our model was derived from a broad patient population, including patients from all populated continents with a wide range of prior inhaled treatments (from short-acting bronchodilators only to ICS/LAMA/LABA) and exacerbation histories in the prior year (0 to >2). The geographically comprehensive range of regions that were included, encompassing different standards of care and diversity in patient behavior and characteristics, should improve the model’s generalizability.

Furthermore, to the best of our knowledge, our models are the first to predict absolute exacerbation rates for patients on various pharmacological treatments. While most predictive models for COPD exacerbations report relative risks according to various patient factors, the ACCEPT model also predicted absolute rates for different patient characteristics. However, it is difficult to compare performance metrics between these models as they are influenced by the follow-up duration of the source clinical trials and the prevalence of exacerbations in the population. Notably, in contrast to the current work, while the ACCEPT source population had longer follow-up on average, it did not include any patients without prior exacerbations in the previous year, exacerbation rates were not predicted according to possible future pharmacological treatments, and the role of eosinophils was not considered, which, as we have shown, is essential in predicting response to ICS-containing therapy. To the best of our knowledge, this is the first description of the application of machine learning to the prediction of exacerbation rates in patients with COPD. Although previous studies have used machine learning techniques to assess COPD-related problems, previously published predictive models of exacerbation risk in COPD have not utilized machine learning.

Several limitations of our study population should also be noted. None of the clinical trials used to develop the models included patients with mild airflow obstruction, patients with a concurrent asthma diagnosis, or never-smokers. Thus, the model cannot be considered reliable for these patient groups. Furthermore, although the overall patient population was broad, some therapies were assessed primarily in patients with low risk (e.g. monotherapy) or high risk (e.g. triple therapy) of exacerbations (see Table 1). Therefore, the modeling relied on the assumption that the relative benefits of different treatments follow similar patterns across the span of included patients. The source trials also included only one drug from each class (ICS, budesonide; LAMA, glycopyrrolate; LABA, FF) and have not yet been demonstrated to be generalizable across all drugs in these classes. While clinical trial data provided reliable and unbiased information on treatment response and a wide selection of potential predictors, there may be differences in relative treatment benefits in clinical trials versus real-world clinical practice. Future studies are needed to validate our models during real-world use and determine whether predictions are generalizable at the drug class level, in order to optimize their utility in clinical practice.

Some of the prognostic factors included may not be regularly available in clinical practice, particularly in primary care, limiting the practical applicability of the full model. For this reason, a simplified model was developed with only three predictors (exacerbation history, eosinophil count, and prior ICS use). Performance metrics were approximately 10% greater in the full model than the simplified model (area under the ROC curve 0.71 versus 0.65; median absolute difference 0.77 versus 0.87). The simplified model may be particularly useful in primary care situations when up-to-date spirometry and CAT score assessments are unavailable. However, we also aimed for the full model to be parsimonious, recognizing the risk of overfitting and the effort involved to utilize a large number of risk factors. Therefore, not all predictors that were identified in machine learning were included in the final model. In general, those that were not included
tended to consistently appear relatively low in priority order compared with the factors that were included in the model or, alternatively, were highly related to factors that were included.

In conclusion, we developed two models to predict exacerbation rates for patients with COPD receiving treatment with various combinations of ICS, LAMA, and LABA. These models illustrate the various risk factors that should be considered when judging the exacerbation risk of individual patients with COPD, and may help inform treatment decision-making, selection of clinical trial populations, and assessment of population-level health risks.

**Ethics approval and consent to participate**
Ethics approval and consent to participate information can be found in the primary publications for the studies from which data were pooled.

**Consent for publication**
Not applicable.

**Author contributions**
- **Dave Singh**: Investigation; Writing – review & editing.
- **John R. Hurst**: Investigation; Writing – review & editing.
- **Fernando J. Martinez**: Investigation; Writing – review & editing.
- **Klaus F. Rabe**: Investigation; Writing – review & editing.
- **Mona Bafadhel**: Investigation; Writing – review & editing.
- **Martin Jenkins**: Conceptualization; Formal analysis; Methodology; Writing – review & editing.
- **Domingo Salazar**: Conceptualization; Formal analysis; Methodology; Writing – review & editing.
- **Paul Dorinsky**: Conceptualization; Methodology; Writing – review & editing.
- **Patrick Darken**: Conceptualization; Methodology; Writing – review & editing.

**ORCID iDs**
- Dave Singh: https://orcid.org/0000-0001-8918-7075
- Klaus F. Rabe: https://orcid.org/0000-0002-7020-1401

**Acknowledgements**
We thank all the patients and their families, and the team of investigators and research staff involved in the studies that contributed to this work. We thank Mattis Gottlow, Aline Gendrin Brokmann, David Svensson, Bart Willigers, and Jack Nyberg for their valuable contributions to these analyses. Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). This study, as well as the studies that contributed to the development of the prediction models, were supported by AstraZeneca. Medical writing support, under the direction of the authors, was provided by Julia King, PhD, CMC Connect, McCann Health Medical Communications, funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by AstraZeneca. The funder of the study had a role in study design, data collection, data analysis, data interpretation, and writing of the report. The authors had full access to all the data in the study and accept responsibility for the decision to submit for publication.

**Conflict of interest statement**
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DSi reports personal fees from AstraZeneca during the conduct of the study and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, GossamerBio, Menarini, Mundipharma, Novartis, Peptinnova, Pfizer, Pulmatrix, Theravance, and Verona, outside the submitted work. JRH reports personal fees from AstraZeneca during the conduct of the study and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, and Novartis, outside the submitted work. FJM reports grants, personal fees, and non-financial support from AstraZeneca during the conduct of the study; grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, and Novartis, outside the submitted work. FD reports personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl Therapeutics, Sunovion, Theravance, and Verona; grants and personal fees from Sanofi; personal fees from Circassia, Innoviva, and Mylan; and grants from...
Altavant, outside the submitted work. KFR reports grants and personal fees from AstraZeneca and Boehringer Ingelheim; personal fees from Chiesi, Novartis, Regeneron, Roche, and Sanofi, outside the submitted work. MB reports grants from AstraZeneca; honoraria from AstraZeneca, Chiesi, and GlaxoSmithKline; and is on the scientific advisory board for AlbusHealth and ProAxs. MJ, DSa, and PDo are employees of AstraZeneca and hold stock and/or stock options in the company. PDo is a former employee of AstraZeneca and previously held stock and/or stock options in the company.

Availability of data and material
Data from the clinical trials included in this analysis may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supplemental material
Supplemental material for this article is available online.

References
1. Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med 2017; 128: 85–91.
2. Suissa S, Dell’Amiello S and Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957–963.
3. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422.
4. Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLOS ONE 2014; 9: e101228.
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Report, 2021. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf
6. Müllervá H, Shukla A, Hawkins A, et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open 2014; 4: e006171.
7. Santibáñez M, Garrastazu R, Ruiz-Nuñez M, et al. Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease. PLOS ONE 2016; 11: e0158727.
8. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med 2010; 363: 1128–1138.
9. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018; 6: 117–126.
10. Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019; 7: 745–756.
11. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435–442.
12. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6: 747–758.
13. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New Engl J Med 2020; 383: 35–48.
14. Hoogendoorn M, Feenstra TL, Boland M, et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. Int J Chron Obstruct Pulmon Dis 2017; 12: 3183–3194.
15. Adibi A, Sin DD, Safari A, et al. The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. Lancet Respir Med 2020; 8: 1013–1021.
16. Annavarapu S, Goldfarb S, Gelb M, et al. Development and validation of a predictive model to identify patients at risk of severe
COPD exacerbations using administrative claims data. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 2121–2130.

17. Yi ACA, Loh CH, Tiew PY, et al. A clinical prediction model for hospitalized COPD exacerbations based on ‘treatable traits’. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 719–728.

18. Ichinose M, Fukushima Y, Inoue Y, et al. Long-term safety and efficacy of budesonide/glycopyrrolote/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 2993–3002.

19. Kerwin EM, Ferguson GT, Mo M, et al. Bone and ocular safety of budesonide/glycopyrrolote/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. *Respir Res* 2019; 20: 167.

20. Ferguson GT, Papi A, Anzueto A, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. *Eur Respir J* 2018; 52: 1801334.

21. Hanania NA, Papi A, Anzueto A, et al. Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. *ERJ Open Res* 2020; 6: 00187-2019.

22. Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolote/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. *Chest* 2017; 151: 340–357.

23. Hanania NA, Tashkin DP, Kerwin EM, et al. Long-term safety and efficacy of glycopyrrolote/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. *Respir Med* 2017; 126: 105–115.

24. Lipworth BJ, Collier DJ, Gon Y, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolote/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 2969–2984.

25. Friedman JH. Stochastic gradient boosting. *Comput Stat Data An* 2002; 38: 367–378.

26. Foster JC, Taylor JM and Ruberg SJ. Subgroup identification from randomized clinical trial data. *Stat Med* 2011; 30: 2867–2880.

27. Lipkovich I, Dmitrienko A and D’Agostino BR Sr. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials. *Stat Med* 2017; 36: 136–196.

28. Hothorn T and Zeileis A. partykit: a modular toolkit for recursive partitioning in R. *J Mach Learn Res* 2015; 16: 3905–3909.

29. Zeileis A, Hothorn T and Hornik K. Model-based recursive partitioning. *J Comput Graph Stat* 2008; 17: 492–514.

30. Zeileis A and Hothorn T. Parties, models, mobsters: a new implementation of model-based recursive partitioning in R. Comprehensive R Archive Network. https://www.zeileis.org/papers/Psychoco-2014.pdf

31. Loh WY, He X and Man M. A regression tree approach to identifying subgroups with differential treatment effects. *Stat Med* 2015; 34: 1818–1833.

32. Loh WY, Man M and Wang S. Subgroups from regression trees with adjustment for prognostic effects and postselection inference. *Stat Med* 2019; 38: 545–557.

33. Hastie T, Tibshirani R and Friedman J. *The elements of statistical learning: data mining, inference and prediction*. Springer, 2001. https://hastie.stanford.edu/toc.pdf.

34. Halpin DMG, Dransfield MT, Han MK, et al. The effect of exacerbation history on outcomes in the IMPACT trial. *Eur Respir J* 2020; 55: 1901921.

35. Kerkhof M, Freeman D, Jones R, et al. Predicting frequent COPD exacerbations using primary care data. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 2439–2450.

36. Bertens LC, Reitsma JB, Moons KG, et al. Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2013; 8: 493–499.

37. Stanford RH, Nag A, Mapel DW, et al. Claims-based risk model for first severe COPD exacerbation. *Am J Manag Care* 2018; 24: e45–e53.

38. Ställberg B, Lisspers K, Larsson K, et al. Predicting hospitalization due to COPD exacerbations in Swedish primary care patients using machine learning – based on the ARCTIC study. *Int J Chron Obstruct Pulmon Dis* 2021; 16: 677–688.

39. Tavakoli H, Chen W, Sin DD, et al. Predicting severe chronic obstructive pulmonary disease exacerbations. Developing a population surveillance approach with administrative data. *Ann Am Thorac Soc* 2020; 17: 1069–1076.